Anthony Wynshaw-Boris.

Patches within one case sample got a similar pattern of labeling. We noticed heterogeneity between case samples with regards to the layers and the cell types which were most unusual. Samples obtained from a 9-year-older boy with autism demonstrated the clearest display of a patch phenotype, with reduced expression found across multiple independent markers within a 5.8-mm diameter patch of cortex . Patches were identified in both dorsolateral prefrontal cortex and posterior superior temporal cortex . No abnormal expression patterns of any markers were recognized in the occipital cortex in 3 case samples or in the posterior excellent temporal cortex or occipital cortex in 3 control samples.Acceleron recieves $1.5 million MDA grant for ACE-031 clinical research in Duchenne Muscular Dystrophy Acceleron Pharma, Inc., a biopharmaceutical organization developing novel therapeutics that modulate the growth of cells and cells including muscle mass, bone, fat, red blood cells and the vasculature, today announced it’s been awarded a $1.5 million grant from the Muscular Dystrophy Association to aid clinical research of ACE-031 in Duchenne Muscular Dystrophy , a disabling neuromuscular disease in which patients experience a progressive loss of muscle power and mass. ACE-031 is an investigational protein therapeutic designed to build up muscle and increase power by blocking proteins that inhibit muscle tissue growth and power. We are honored to become recognized and supported by the Muscular Dystrophy Association as we function collectively to develop promising therapies for the treating individuals with Duchenne Muscular Dystrophy, said John Knopf, PhD, CEO of Acceleron.